Cargando…
Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters
BACKGROUND/AIM: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, which has been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationship with metabolic parameters in pso...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Scientific and Technological Research Council of Turkey
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350829/ https://www.ncbi.nlm.nih.gov/pubmed/30762319 http://dx.doi.org/10.3906/sag-1712-192 |
_version_ | 1783557342209507328 |
---|---|
author | KORKMAZ, Selma SAYILAN ÖZGÜN, Gülben |
author_facet | KORKMAZ, Selma SAYILAN ÖZGÜN, Gülben |
author_sort | KORKMAZ, Selma |
collection | PubMed |
description | BACKGROUND/AIM: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, which has been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationship with metabolic parameters in psoriasis vulgaris patients both with and without metabolic syndrome (MetS). MATERIALS AND METHODS: Fifty-three patients and 26 healthy controls were included in this study. Serum adropin levels, fasting blood glucose, fasting serum insulin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and triglyceride levels of all participants were analyzed. Enzyme-linked immunosorbent assay was used to measure serum adropin levels. RESULTS: Serum adropin levels were 2.94 ± 0.56 ng/mL in psoriatic patients without MetS, 2.49 ± 0.77 ng/mL in psoriasis patients with MetS, and 3.37 ± 0.71 ng/mL in the control group. Multivariate logistic regression analysis was used to evaluate adropin decreases in psoriasis patients as an independent predictor of the presence of MetS. CONCLUSION: The serum levels of adropin in psoriasis patients were significantly lower in the presence of MetS, and this decrease was more prominent than in those without MetS. Adropin may be a contributing factor for metabolic disorders and the development of MetS in psoriasis patients. |
format | Online Article Text |
id | pubmed-7350829 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Scientific and Technological Research Council of Turkey |
record_format | MEDLINE/PubMed |
spelling | pubmed-73508292020-07-13 Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters KORKMAZ, Selma SAYILAN ÖZGÜN, Gülben Turk J Med Sci Article BACKGROUND/AIM: Adropin is a peptide-structure hormone that plays a role in preventing the development of insulin resistance, which has been linked to obesity and metabolic regulation. The purpose of this study is to assess serum adropin levels and their relationship with metabolic parameters in psoriasis vulgaris patients both with and without metabolic syndrome (MetS). MATERIALS AND METHODS: Fifty-three patients and 26 healthy controls were included in this study. Serum adropin levels, fasting blood glucose, fasting serum insulin, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, and triglyceride levels of all participants were analyzed. Enzyme-linked immunosorbent assay was used to measure serum adropin levels. RESULTS: Serum adropin levels were 2.94 ± 0.56 ng/mL in psoriatic patients without MetS, 2.49 ± 0.77 ng/mL in psoriasis patients with MetS, and 3.37 ± 0.71 ng/mL in the control group. Multivariate logistic regression analysis was used to evaluate adropin decreases in psoriasis patients as an independent predictor of the presence of MetS. CONCLUSION: The serum levels of adropin in psoriasis patients were significantly lower in the presence of MetS, and this decrease was more prominent than in those without MetS. Adropin may be a contributing factor for metabolic disorders and the development of MetS in psoriasis patients. The Scientific and Technological Research Council of Turkey 2019-02-11 /pmc/articles/PMC7350829/ /pubmed/30762319 http://dx.doi.org/10.3906/sag-1712-192 Text en Copyright © 2019 The Author(s) This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Article KORKMAZ, Selma SAYILAN ÖZGÜN, Gülben Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters |
title | Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters |
title_full | Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters |
title_fullStr | Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters |
title_full_unstemmed | Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters |
title_short | Serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters |
title_sort | serum adropin levels in psoriasis vulgaris and its relation with metabolic parameters |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350829/ https://www.ncbi.nlm.nih.gov/pubmed/30762319 http://dx.doi.org/10.3906/sag-1712-192 |
work_keys_str_mv | AT korkmazselma serumadropinlevelsinpsoriasisvulgarisanditsrelationwithmetabolicparameters AT sayilanozgungulben serumadropinlevelsinpsoriasisvulgarisanditsrelationwithmetabolicparameters |